Potential solutions to address the significant clinical trial design gaps for variant RCC histologies may include the systematic inclusion of these variants in dedicated cohorts within larger trials, as well as basket/umbrella trial designs based on shared biomarker profiles (e.g., NF-2-altered, ALK-rearranged, or SMARCB1-deficient tumors) [127,129]. Here, NF2 is linked to renal cell carcinoma.